Date: 2013-03-18
Type of information: R&D agreement
Compound: small molecule inhibitors of the ubiquitin system
Company: GSK (UK) Proteologics (Israel)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: Proteologics, a drug developer based on the ubiquitin system, announced today that, under the terms of the 3- year original collaboration agreement signed with GSK in March 2010, the parties have agreed to extend the collaboration for an additional year. The company has indicated that Proteologics is hopeful that by the end of the collaboration it will be able to deliver to GSK a selective inhibitor of an E3 Ligase.
Financial terms:
Latest news:
